Daily Market Movers 1-3-08

FEATURED COMPANY

MINDPIX CORPORATION (OTC: MNDP)

Detailed Quote: http://www.otcpicks.com/quotes/MNDP.php

Company Profile: http://www.otcpicks.com/mindpix/mindpix.htm

Mindpix is positioned as a powerful and positive media group of companies. Ultraflex Fitness, UltraFlex Medical, Mindpix Production, and Mindpix Development are all actively engaged in “for profit” productions or projects.

UltraFlex Fitness: Developing and marketing the patent pending UltraFelx Fitness Rod. UltraFlex Fitness promotes a new style of resistance training called Target Perfect Resistance.

UltraFlex Medical: UltraFlex Medical is poised to make significant inroads to the $11 Billion US outpatient rehabilitation market. Ultraflex medical is already working with rehab industry professionals to create unique and proprietary physical therapy curriculum.

Mindpix Production: Mindpix continues to produce, direct, and provide post-production services for promising documentaries and other niche profitable projects.

MNDP News:

December 31 - Mindpix Management 2007 Year-End Letter to Shareholders

Management of Mindpix (OTCBB: MNDP) has determined it necessary to give a 2007 year-end update on the progress of the UltraFlex fitness device as well as make our shareholders aware of recent material decisions regarding previously announced press releases.

Looking back at the year in review Mindpix has reached many important UltraFlex milestones including completing a successful twelve-week UltraFlex fitness and weight loss study, producing workout DVDs, production of a "man on the street" featuring first-time users, signed the 2007 Female Presenter of the Year Forbes Riley, introducing TheraFlex to the Physical Therapy and Training to Physiotherapy Associates, acquiring testimonials from fitness instructors and personal trainers, a physical therapy training DVD, signing a major celebrity, introducing new physical therapy and active senior products (TheraFlex) to name a few. It has been quite a year and the outlook for 2008 looks equally promising.

Mindpix has decided for strategic reasons not to air UltraFlex commercials in conjunction with Supplements To Go Ms. Fitness World Pageant. Mindpix had previously announced (Nov 19th 2007) that it intended to air two sixty-second commercials during the pageant broadcast on Fox Sport News beginning January 1, 2008. It was determined that airing the commercials prior to our infomercial national launch would not make good marketing sense particularly due to the fact that our celebrity talent would not be featured in the commercials. Mindpix holds the option to air commercials beginning in May 2008 during the Supplements To Go Ms. Fitness USA Pageant.

Mindpix management also has cancelled the exhibition at the annual Baseball Team Medicine Conference in St. Louis on January 3-5, 2008. A scheduling conflict made it impossible for our medical division team to attend.

Management believes that the marketing strategy in place is sound and looks forward to executing the business plan with profitable results for 2008. Mindpix has benefited from loyal shareholders who have taken the time to review our progress and communicated with us ways in which they can assist us in reaching our business goals.

Mindpix wishes each of you a happy and prosperous new year.

David R. Ballif, CEO
Mindpix Corporation

FEATURED COMPANY

QUOTEMEDIA INC. (OTCBB: QMCI)

Detailed Quote: http://www.otcpicks.com/quotes/QMCI.php

Company Profile: http://www.otcpicks.com/quotemedia/quotemedia.htm

QuoteMedia, Inc. is a leading software developer and provider of real-time streaming financial market information, decision-support, news and research solutions to brokerage, financial services companies, business and media corporations. Among its many leading-edge products lines, the Company offers data feeds, news, dynamic market content solutions, interactive stock research tools, financial applications and real-time wireless applications. QuoteMedia provides data and services for companies such as the NASDAQ, the OTCBB, Dow Jones & Company, Forbes.com, Scotia Capital, Business Wire, Southwest Securities, Regal Securities, FBR Direct, Broadridge Financial Solutions, Inc., AIM Trimark, Zacks Investment Research, ChoiceTrade, QTrade, Schaeffer's Investment Research, Automated Financial Systems, WallStreet*E, and others. For more information, visit www.quotemedia.com.

QMCI News:

December 5 - QuoteMedia Brings Respected Market Data Industry Veteran Onboard; Opens NYC Office

QuoteMedia, Inc. (OTCBB: QMCI), a leading provider of market data, corporate research information and financial applications, announced today the appointment of Mr. George Katsch as Corporate Sales Director, to lead the company’s new office in New York City.

Mr. Katsch brings more than 15 years of experience in selling and supporting financial information and technology solutions to the Brokerage, Financial Service, Media Publishing and Investor Relations industries. Most recently, Mr. Katsch served as Vice President of Sales for FinancialContent, Inc., where he was responsible for business development and sales for the entire North American market. Mr. Katsch has also held key management positions with Standard and Poor’s and Interactive Data Corporation (Comstock), where he managed senior account representatives and support staff. He was principally responsible for maintaining over $50 million in revenues and generating new sales.

“George is very well-known as a successful, skilled professional in our industry, and we’re excited that he is joining the QuoteMedia sales team, heading up our New York office,” said Dave Shworan, CEO of QuoteMedia Ltd. “He brings a wealth of experience to our company, and skill sets that make him an immediately great fit with QuoteMedia, as we continue our explosive growth.”

“From within the industry, I’ve watched QuoteMedia’s remarkable growth over the past few years. I have been very impressed with QuoteMedia’s emergence as a major player in the financial data industry, and the potential for further growth is extraordinary,” said Mr. Katsch. “QuoteMedia is definitely going places, and I’m excited to be a part of it.”

FEATURED COMPANY

RENHUANG PHARMACEUTICALS (OTCBB: RHGP)

Detailed Quote: http://www.otcpicks.com/quotes/RHGP.php

Company Profile: http://www.otcpicks.com/renhuang-pharma/renhuang-pharma.htm

Renhuang Pharmaceuticals, located in Harbin of Heilongjiang Province in Northeast China, is a leading integrated developer, manufacturer and distributor of a broad line of high-quality nutraceutical, natural medicinal and bio-pharmaceutical products. The Company provides three major product lines including the Acanthopanax-based natural medicinal products, Shark Power Health Care series and Traditional Chinese Medicines. Renhuang's key product line is Acanthopanax-based products, an effective natural medicine in treating depression and melancholy and offering various other health benefits. By controlling an estimated 70% of China's natural resource of Acanthopanax (also known as Siberian Ginseng), the Company has a dominant market position in Acanthopanax-based natural medicines. The Company distributes its products through a multi-layer sales network of over 2000 sales agents. Its products are not only sold nationwide but also exported to Russia and Southeast Asia. Renhuang has established a multi-channel research and development infrastructure composed of in-house researchers, a post-doctoral working center, and collaboration with well known institutions and scientists. In manufacturing, the Company strictly follows the international GMP certified quality standards and system by utilizing cutting-edge technologies, the state of the art equipment, and the proprietary innovative and award winning processes. For more information about Renhuang Pharmaceuticals, visit www.renhuang.com.

RHGP News:

December 17 - StockGuru Announces a New Executive Interview With Mr. Li Shaoming of Renhuang Pharmaceuticals

John Pentony, Publisher of Stockguru.com announced that the company has posted a new podcast interview featuring Renhuang Pharmaceuticals, Inc. (OTCBB: RHGP). Pentony interviews Mr. Li Shaoming, CEO and Chairman of the Board, for Renhuang Pharmaceuticals. In the interview Mr. Li discusses the company and its recent news from the company including its recently announced Olympic year prime time television ad space on China Central Television (also known as "CCTV").

To listen to the interview, visit www.stockguru.com/podcasts/?p=21.

FEATURED COMPANY

BIGSTRING CORPORATION (OTCBB: BSGC)

Detailed Quote: http://www.otcpicks.com/quotes/BSGC.php

Company Profile: http://www.otcpicks.com/bigstring/bigstring.htm

BigString Corporation, through its subsidiary, BigString Interactive, Inc., provides email services. It offers BigString, which is a Web-based, POP3 server email service solution that allows the user to edit, recall, cancel, and erase the email, as well as insert or delete attachments, even after the email has been sent out and opened. The company also provides BigString Beta 2.0 that offers erasable, recallable, and self destroying applications, non-printable and non-forwardable emails, set time or number of views, and masquerading to protect the sender's privacy and security. BigString Beta 2.0 also provides spam filters, virus protection, and large-storage web-based email accounts. The company's products include BigString Free, which provides the features of BigString Beta 2.0, and includes 1GB of storage and permits the user to send unlimited emails per month; BigString Premium, which offers the features of the BigString Free account, plus vanity domains, POP3 access using any email client, 2GB of storage, and 30 minute video email; and BigString Business that offers the features of the BigString Premium account, plus 10 email accounts, 20GB of storage, global filter notification, and email management. BigString Corporation also offers BigString Marketer Pro, which provides an enterprise marketing software application which allows for the sending of interactive video email commercials that can be programmed to self-destruct at a set time; and BigString Marketer SMB, a hosted video email marketing platform for small and medium size businesses. The company was founded in 2003. It was formerly known as Recall Mail Corporation and changed its name to BigString Corporation in 2005. Bigstring Corporation is based in Red Bank, New Jersey.

BSGC News:

December 18 - BigString Corporation Launches Facebook Application Enabling Users to Send Self-Destructing Videos

BigString Corporation (OTCBB: BSGC) has launched an application for Facebook that enables users to record or upload videos that can be programmed to self-destruct at a specific time or after a set number of views. This is part of a new BigString initiative to develop social networking messaging applications built around the company's core technology.

The video application will allow users to send private self-destructing video messages or to post public video messages to the recipient’s wall. Users can record a video message directly to the application or upload a pre-existing message.

Darin Myman, President and CEO of BigString Corporation, noted that "Video message privacy and security is very important in a world where you can very easily find your personal videos being put up without your permission on sites such as YouTube. Social networks such as Facebook interface well with BigString’s proprietary messaging technology. We provide added value to websites focused on social networking, online dating or user-generated content where protecting a user’s privacy is a major consideration."

FEATURED COMPANY

EBENEFITSDIRECT (OTC: EBFD)

Detailed Quote: http://www.otcpicks.com/quotes/EBFD.php

Company Profile:
http://www.otcpicks.com/ebenefits-direct/ebenefits-direct.htm

eBenefits Direct, Inc. is a nationwide leader in the direct marketing and distribution of a wide range of health and life insurance products to individuals, families and groups. By utilization of its many call centers across the country it enables an individual to efficiently purchase health and life insurance as well as medical and discount service programs. The company has revolutionized the way health and life insurance has historically been sold. eBenefits Direct, Inc.'s approach is through many mass distribution areas such call centers, the internet and massive lead generation programs.

EBFD News:

December 14 - eBenefits Direct Subsidiary, L.A. Marketing Plans, Launches Call Center in Portland, Maine, to Market Healthcare Programs to Uninsured Individuals Across the U.S.

L.A. Marketing Plans LLC, a wholly owned subsidiary of eBenefits Direct, Inc. (OTC: EBFD), announced recently that its exclusive RightHealth program has expanded its operation with a new call center facility located in Portland, Maine. This addition will allow RightHealth to reach a significant market of uninsured consumers.

“We are very pleased to be able to offer the RightHealth portfolio of products for distribution through this call center. RightHealth, a medical discount program, provides a helpful solution to individuals that do not qualify for or cannot afford major medical insurance. Through the association membership, individuals are provided access to medical discounts and additional defined insured benefits. The launch of this new facility will help expand and promote the RightHealth programs,” said Rob Michaelson, President of L.A. Marketing Plans LLC.

RightHealth provides members a combination of discounts on healthcare costs, including physicians, dental and vision, and access to a variety of other valuable healthcare features, such as defined accident insurance coverage, including accident disability income and an emergency rescue plan, through membership in America's Health Care Consumer Association.

The RightHealth programs are available through Access Plans USA, Inc. (www.accessplansusa.com), a publicly traded company. Access Plans is a nationwide distributor of health insurance and non-insurance healthcare programs that provide access to affordable healthcare for the growing number of uninsured and/or underinsured in the United States. For more information on the RightHealth programs, visit www.righthealthplan.com.

STOCKS TO WATCH

SUNRISE CONSULTING (OTC: SNRS)
"Up 233.33% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/SNRS.php

Sunrise Consulting Group, Inc. CEO Raymond Chin, has been based in Hong Kong for the last 10 years and has established relationships with Chinese Companies that would like to go public and be listed on US exchanges such as (OTC.PK, OTC.BB, NASDAQ, AMEX, & NYSE). These companies are mostly from mainland China and Hong Kong, with contacts also in Laos, Vietnam, Malaysia, Australia and others in the Pacific Rim & Southeast Asia. The company's goal is to become the premier Investment Banking Firm servicing small to medium sized companies in China and throughout Asia. Management has had success with consulting with public companies in the United States as well.

SNRS News:

January 3 - Sunrise Consulting Group, Inc. Signs Letter of Intent With Cao Tian Iron Ore Mines, Hunan Province, China

Sunrise Consulting Group, Inc. (OTC: SNRS), signed a Letter of Intent with Cao Tian Iron Ore Mines, ZhuZhou City, Hunan Province, PRC "CHINA" for the concession rights to mine this particular area of that region for at least 30 years. The letter sets forth the basic terms and conditions under which both parties have agreed to.

Sunrise Consulting Group, Inc. will issue 1 million shares of preferred stock to own 100% of the mining rights when signing the final agreement. These shares will have guaranteed buyback options within 24 months at $1.00 USD per share. Total buyback will be $1,000,000 USD.

This particular parcel of land stretches to an astounding 3 square miles and the mountain has an estimated 3 million tons of Iron Ore that can be mined over the next 30 years. The company plans to rapidly move forward in accordance with terms and conditions set forth in the proposed agreement (LOI).

OREGON PACIFIC BANCORP (OTCBB: OPBP)
"Up 29.83% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/OPBP.php

Oregon Pacific Bancorp operates as the holding company for Oregon Pacific Banking Co., which provides various banking products and services to commercial enterprises, governmental entities, and individuals in Lane, Douglas, and Coos counties, as well as on the central Oregon coast. The company offers various consumer deposit products, including noninterest bearing checking accounts, interest bearing checking and savings accounts, money market accounts, and certificates of deposit. It provides consumer loans, such as secured and unsecured personal loans, home equity loans, personal lines of credit, and motor vehicle loans; real estate construction loans; residential mortgage loans; and commercial loans. Further, the company offers trust and asset management services, investment services, brokerage services, online banking services, banking on call, automated teller machines, debit cards, safe deposit boxes, letters of credit, travelers' checks, direct deposit of payroll, social security, dividend payments, and automatic payment of insurance premiums and mortgage loans. As of December 31, 2006, Oregon Pacific Bancorp operated through its main office and a full-service Safeway store branch in Florence, as well as two branches in Roseburg and Coos Bay, Oregon. The company was founded in 1979 and is headquartered in Florence, Oregon.

OPBP News:

January 2 - Oregon Pacific Bancorp Announces Reverse Stock Split and Plan to De-register

Oregon Pacific Bancorp (OTCBB: OPBP) (the "Company") announced that its Board of Directors has approved a plan to de-register the Company's common stock under the Securities Exchange Act of 1934, as amended, and, therefore, terminate its obligations to file reports with the Securities and Exchange Commission. This transaction would be accomplished through a reverse stock split of common shares of 1 for 500. All stockholders with less than one share after the reverse-split will have their partial shares cashed out at a price of $13.00 per pre-split share. Following the buyback of the partial shares, stock will split at 500 for 1. Shares of common stock held by shareholders owning more than 500 shares before the reverse split will remain outstanding and will be unaffected by the two transactions. The date for determining which shareholders shall be cashed out is January 4, 2008.

If, after completion of the transaction, Oregon Pacific Bancorp has fewer than 300 stockholders of record, the Company intends to terminate the registration of its common stock under the Securities and Exchange Act of 1934, as amended, and become a non-reporting company. If that occurs, the Company will no longer file periodic reports with the Securities and Exchange Commission ("SEC"), including annual reports on Form 10-K and quarterly reports on Form 10-Q, and will no longer be subject to the SEC's proxy rules.

The Board of Directors received a fairness opinion from an independent appraisal firm, Southard Financial, that the price of $13.00 per share cash out price to be paid to shareholders owning less than 500 shares is fair, from a financial point of view, to Company stockholders. The proposed transaction is subject to approval by the holders of a majority of the issued and outstanding shares of the Company's common stock. Stockholders will be asked to approve the transaction at a special meeting of stockholders, currently expected to be held in March 2008.

The proposed plan should result in a direct cost savings to Oregon Pacific in the near term from the elimination of SEC reporting requirements. Also, this plan will allow Oregon Pacific to avoid the substantial additional costs associated with the compliance and auditing requirements of the Sarbanes-Oxley Act of 2002, Section 404 ("SOX 404"). "We anticipate that the reduced burden on management will allow our officers the opportunity to be more responsive to the needs of their clients and the communities they serve," stated CEO James P. Clark. "By remaining a progressive, independent, community bank we can best serve our employees, stockholders and customers."

The Company has filed a preliminary proxy statement and Schedule 13E-3 with the SEC outlining the transaction. All stockholders are advised to read the definitive proxy statement and Schedule 13E-3 carefully when these documents are available. Stockholders may obtain a free copy of the proxy statement and Schedule 13E-3 at the SEC's web site at www.sec.gov. Oregon Pacific Bancorp will also mail a copy of the definitive proxy statement prior to the special meeting to its stockholders entitled to vote at the special meeting.

For more information about the above transaction, contact Joanne Forsberg, Secretary, at (541) 997-7121.

BLACK DRAGON RESOURCE COMPANIES (OTC: BDGR)
"Up 95.24% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/BDGR.php

Black Dragon Resource Companies, Inc. engages in the acquisition, development, production, and sale of oil and gas, and natural gas properties in the United States. It produces oil and natural gas from marginal stripper wells, whose production has slowed to 1/2 barrels of crude oil per day or less. The company was incorporated in 1996 as Vita Health, Inc. and changed its name to Vita Warehouse Company, Inc. in 1999. Further, it changed its name to Texas Diversified Distributors, Inc. in 2001; to Black Dragon Resource, Inc. in February 2004; and to Black Dragon Resource Companies, Inc. in December 2004. Black Dragon Resource Companies, Inc. is headquartered in Oil City, Louisiana.

BDGR News:

January 3 - Black Dragon Announces Significant Further Progress on the Joint Venture Funding Negotiations

On January 2, 2008, Mr. Joe Lanza, President of Black Dragon Resource Companies, Inc. (OTC: BDGR) announced that negotiations with a Joint Venture Funding Partner, as previously announced last week, were close to being completed.

Mr. Lanza reiterated that the Funding Joint Partner has agreed to provide the Joint Venture with a significant investment of at least $100,000,000. He added that the Joint Venture Partner had just confirmed to its satisfaction that the Company's oil and gas reserves have a value of at least $2.7 billion dollars and that it was prepared to move forward with the transaction, subject to finalization of its audit, which should be completed within a week.

Mr. Lanza also reported that the Joint Venture Partner and the Company had agreed in principle to all terms of the Joint Venture Agreement, the completion of which is now subject only to Counsel's review.

Further, and perhaps most significant, Mr. Lanza reported that he had met with the proposed new management team who, according to Mr. Lanza, has the extensive experience in both oil and gas technology and in production management to ensure the success of the Joint Venture and the full and proper development of Black Dragon's extensive resources.

Mr. Lanza concluded by stating that he was most impressed with the proposed management team and upon the Funding of the Joint Venture and the finalization of all details of the Joint Venture that he believed his goal for the Company would have been realized and that he would promptly resign. All Black Dragon shareholders, he concluded, will be greatly benefited by the new Joint Venture structure, and with the expansion of Black Dragon operations, which could only increase shareholder value.

Management believes that all details of the Joint Venture will be finalized prior to the Annual Meeting on January 16, 2008, so that the matter could be considered by the Stockholders at that time.

MILLENNIUM CELL INCORPORATED (NASD: MCEL)
"Up 30.11% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/MCEL.php

Millennium Cell, Inc. develops hydrogen batteries for use primarily in portable electronic devices for the military, medical, industrial, and consumer markets. The hydrogen batteries comprise a fuel cell and hydrogen fuel cartridge technology. The fuel blends used in the hydrogen battery technology are comprised of a combination of water, sodium borohydride, and other chemicals. The hydrogen produced by its hydrogen fuel cartridge technology is converted into electricity by a fuel cell. The company develops the technology in partnership with corporate and government entities. It also licenses its fuel cartridge technology to fuel cell manufacturers, original equipment manufacturers, and other product-focused entities. The company has a strategic relationship with The Dow Chemical Company to collaborate on the design, development, and commercialization of proton exchange membrane fuel cell power systems and compatible Hydrogen on Demand fuel cartridges for use in portable electronic devices; and with Horizon Fuel Cell Technologies Pte, Ltd. focused on the commercialization of fuel cell based power products. Millennium Cell was founded in 1998 and is based in Eatontown, New Jersey.

MCEL News:

January 3 - Millennium Cell and Horizon Fuel Cell Provide Detailed Plans for HydroPak(TM) Portable Power Product

Latest Version to be Shown at CES and Tactical Power Source Conferences in January 2008

Major OEMs, Retailers and Distributors to Receive Samples in February

UL Certification Process Initiated, Customer Shipments Targeted for Q3

Millennium Cell Inc. (NASD: MCEL) and Horizon Fuel Cell Technologies announced the completion of a pre-production version of the HydroPak™ portable power generator that incorporates a unique water-activated cartridge system. The HydroPak™ product combines Horizon’s fuel cells with Millennium Cell’s Hydrogen on Demand® storage technology to offer a clean and quiet power generator for use by consumers and professionals for emergency and recreational purposes.

This power source is a high energy alternative to lead acid battery packs and portable generators. The HydroPak™ system, together with each cartridge:

• Provides infinite shelf life and enough energy to recharge an average notebook computer 8 to 10 times.
• Can run indoors with quiet operation and zero harmful emissions.
• Is quieter, lighter and smaller than generators.
• Stores more energy than possible with batteries.
• Has a lower cost than any similar fuel cell device.

The HydroPak™ will debut at the Consumer Electronics Show (CES) at the Las Vegas Convention Center in South 1, Booth #21850H from Jan. 7-10. The system will also be shown to the U.S. military at the Tactical Power Sources Summit 2008 at the Georgetown University Conference Center in Washington, D.C. on Jan. 29-30. These conferences are the first venues where potential users and distributors can see HydroPak™ emergency power products publicly in the United States.

The HydroPak™ is designed with a common AC outlet and two USB connectors to charge or operate low power devices such as portable lights, notebook computers, portable televisions and ad hoc communications networks for more than 14 continuous hours when needed. The planned retail pricing of $400 for the system and $20 for the disposable cartridges will make this solution attractive to both professionals responding to emergencies, as well as consumers desiring power for both backup and recreational needs.

Beginning in February 2008, Horizon and Millennium Cell plan to demonstrate and sample limited numbers of the current pre-production unit to OEM’s, distributors, and key military decision makers. The current design of the unit is in the process of evaluation by Underwriters Laboratories (UL) and it is expected that listing will be received by mid 2008 on this product. Subsequently, several thousand units will be manufactured by Horizon for sale in the second half of 2008. Millennium Cell will have sole responsibility for all sales of the HydroPak™ power generation system in the United States.

Additional products have been identified for development and are expected to be shipped to commercial and government customers for evaluation in 2008 and 2009. A HydroPak Mini™ product prototype for use in consumer devices such as cell phones, PDA’s and portable media players will also be demonstrated for the first time at the conferences in January. The objective of showing this unit is to gauge interest for a less expensive, smaller power source with unlimited shelf life and silent power for smaller portable communications and electronics devices.

“We are excited about the prospects for the HydroPak™ line of products, beginning with the commercialization of the first water-activated portable power system in 2008 and followed shortly by others in 2009. We believe that these fuel cell power products possess a potent combination of convenience, performance and economics that are unique in the marketplace and will fill a void that exists today,” commented George Gu, CEO of Horizon Fuel Cell Technologies.

In October, the two companies signed a Letter of Intent (LOI) to collaboratively develop, market, and sell certain portable fuel cell power products. The partnership is aimed at launching a number of commercial and consumer products that combine Horizon’s commercial grade fuel cells with hydrogen cartridges developed by Millennium Cell. Definitive documentation that amends the August 2007 license agreement between Horizon and Millennium Cell to reflect the terms of the LOI is expected to be completed in the first quarter of 2008.

“Millennium Cell considers the HydroPak™ product line as a cornerstone in our product strategy and we are dedicating significant resources to support product introduction into the marketplace beginning in 2008. The initial reaction from OEM’s and potential distributors for this product has been very positive and we plan to generate our first commercial revenues through aggressively marketing and selling this innovative family of products,” commented Adam Briggs, President of Millennium Cell.

PHYTOMEDICAL TECHNOLOGIES (OTCBB: PYTO)
"Up 24.14% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/PYTO.php

PhytoMedical Technologies, Inc., together with its wholly owned subsidiaries, operates as an early stage research-based biopharmaceutical company. It focuses on the identification, acquisition, development, and commercialization of plant-derived pharmaceutical and nutraceutical compounds targeting cachexia, obesity, and diabetes. The company develops BDC-03, a plant derived compound that has capacity to decrease the deposition of fat and lower cholesterol. Additionally, through a cooperative research and development agreement, PhytoMedical engages in synthesizing the active components of various polyphenolic compounds found in cinnamon bark and characterizing their beneficial health effects in cell cultures systems, animals, and humans. The company, formerly known as Enterprise Technologies, Inc., was founded in 1986 and changed its name to PhytoMedical Technologies, Inc. in 2004. PhytoMedical Technologies is headquartered in Princeton, New Jersey.

PYTO News:

January 3 - PhytoMedical's Anti-Cancer Compound Effective at Killing Brain Cancer Cells

Novel Class of Patented Anti-Cancer Compounds Demonstrates Significant Ability to Kill Human Glioblastoma (Brain) Cancer Cells, an Extremely Resistant and Often Fatal Strain of Cancer

PhytoMedical Technologies, Inc. (OTCBB: PYTO) (FWB: ET6), announced that research outcomes from ongoing in vitro studies of the Company’s sponsored anti-cancer compounds have successfully demonstrated the ability to kill a strain of human brain cancer cells which is otherwise highly-resistant to currently available drugs.

Led by Dartmouth College researcher Dr. Gordon Gribble, researchers have determined that, one of several patented “bis-intercalator” anti-cancer compounds being developed by PhytoMedical has achieved a 50% or greater cancer cell kill rate at a minimum concentration in studies of the SF-295 strain of human glioblastoma (brain) cancer cells — a significant outcome, given these brain cancer cells’ drug-resistant nature.

“The outstanding results of this human cancer cell study is an extremely important step towards finding a potential solution for treating glioblastoma, an often fatal form of cancer,” commented Greg Wujek, President, CEO of PhytoMedical Technologies, Inc. “The demonstrated cytotoxic effects of this unique patented compound on such a resistant strain of cancer has given us the confidence to move forward in our research and improve upon the concept of bis-intercalation and the promise it holds for the control of cancer.”

In important in vitro experiments, researchers tested several variations of patented bis-intercalator compounds. These compounds have the unique capability to “intercalate” or insert their anti-cancer molecules inside DNA sites of specific cancer cells, thereby preventing the ability of the cancer cells to replicate and ultimately forcing their death.

“We are very happy,” says Alla Kan Director of Dartmouth’s Technology Transfer Office, “that we found a good partner to help us bring these powerful new drugs claimed in Dartmouth College issued patent #6,187,787 to the patient as this is an ultimate goal of our office, to utilize research taking place in our laboratories for the public good.”

Among several compounds tested in vitro against an often fatal strain of human glioblastoma (brain) cells, researchers have identified a high performance compound which requires the least concentration in order to achieve a 50% or greater cancer cell kill rate. This strong activity against glioblastoma cancer cells is a significant achievement given these cells’ strong resistance to currently available anticancer drugs such as Lomustine, Carmustine, Nitrosourea, Hydroxyurea, and Procarbazine.

PhytoMedical’s Cancer Research: Killing Cancer’s DNA

PhytoMedical is developing a novel class of patented anti-cancer agents that have a ‘cytotoxic’ or poisonous affinity for cancer cells and are designed to bind more tightly to cancer cell DNA than many conventional anticancer drugs by a process called bis-intercalation or “double binding,” much like a molecular staple. Because the DNA is the blueprint of life for the cancer cell, such binding stops the replication of the DNA, which prevents the growth of the cancer cell and it dies.

DNA is present in the nucleus of every cell of all living organisms, which are constantly dividing through a process in which the DNA in the nucleus of the original cell replicates itself to be present in the nuclei of the two new (“daughter”) cells. If this replication cannot occur, the cell will die and the organism will eventually stop growing and die. Cancer is characterized by the development of abnormal cells that divide uncontrollably and have the ability to infiltrate and destroy normal body tissue.

At present, anticancer molecules designed to block the replication of DNA do so through “intercalation,” a mechanism in which the drug inserts itself between one set of adjacent base pairs of the DNA. PhytoMedical believes a more effective anticancer strategy is to design molecules (“bis-intercalators”) that can intercalate simultaneously at two DNA sites, thus further increasing the binding between the drug and the DNA of specific cancer cells in order to stop their replication and ultimately resulting in the death of the cancer cell.

CAPITAL GROWTH SYSTEMS (OTCBB: CGSY)
"Up 32.76% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/CGSY.php

Capital Growth Systems, Inc., doing business as Global Capacity Group, Inc., delivers telecom integration services to systems integrators, telecommunications companies, and enterprise customers worldwide. It provides an integrated supply chain management system that streamlines and accelerates the process of designing, building, and managing customized communications networks. The company also provides connectivity services for network integrators who bundle telecommunication solutions to enterprise customers; offers global pricing and quotation software and management services for data communications; and assists customers to reduce connectivity costs and attain understanding and control of their deployed communications network. In addition, the company manages data replication and business continuity environments for multinational corporations and health care institutions. Capital Growth Systems is based in Chicago, Illinois.

CGSY News:

January 3 - Global Capacity and VSNL Global Services Complete Strategic Sourcing Agreement

Partnership Provides Company with Crucial International NOC, Provisioning and Analyst Resources

Global Capacity, Inc., a subsidiary of Capital Growth Systems, Inc. (OTCBB: CGSY) and the telecom industry’s first logistics company, announced that it has signed a strategic sourcing contract with VSNL Global Services Limited (parent: Videsh Sanchar Nigam Limited (NYSE: VSL)), a global leader in outsourced carrier operations.

This agreement enables Global Capacity to efficiently scale operations through the establishment of an international network operations center (NOC), as well as utilize additional network analyst and provisioning resources.

“A high quality, scalable service delivery capability is critical to support the rapid adoption of our solutions by our expanding global customer base,” said Patrick Shutt, Chief Executive Officer for Global Capacity. “By coupling the resources and capabilities of VSNL Global Services Limited with the core expertise and systems of Global Capacity, we have created a cost effective service delivery capability that exceeds our customer’s expectations both immediately and into the future.”

The international operations center, located in Pune, India, will work in conjunction with the Global Capacity network operations center in Waltham, MA, to provide “follow the sun” support for the Company’s increasingly international customer base. The network analyst and provisioning resources will enable the rapid scaling required to implement key customer revenue initiatives as Global Capacity continues to win major contracts.

Additionally, Global Capacity and VSNL Global Services Limited have signed a Letter of Intent to create a business development agreement that enables each company to leverage the other’s portfolio of offerings to its existing customer base.

“We are pleased that Patrick and his team have chosen VSNL Global Services Limited as their strategic sourcing partner,” said V. S. Shridhar, Chief Operations Officer of VSNL Global Services Limited. “We believe Global Capacity has developed a unique model and has an unrivaled group of talented industry experts that are creating tremendous value in the market. There are strong similarities in how our two companies do business, and VGSL is very well positioned to help Global Capacity successfully manage its rapid growth.”

ABOUT GLOBAL CAPACITY

Global Capacity is the operating arm of Capital Growth Systems, Inc. (OTCBB: CGSY). The telecom logistics company provides a fully integrated supply chain management system that streamlines and accelerates the process of designing, building and managing customized communications networks. It offers a comprehensive suite of services to enterprises, systems integrators and carrier customers worldwide. Global Capacity has operational centers in Waltham, MA; Manchester, England and Houston, TX; with offices in Chicago, IL; New York, NY; Minneapolis, MN; and Lisbon, Portugal. For more information, visit www.globalcapacity.com or contact (866) 226-4244.

SOLAR NIGHT INDUSTRIES (OTC: SLND)
"Up 16.22% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/SLND.php

Solar Night Industries, Inc. is a national Modern Energy Company that enables residential and commercial energy users to implement cost-effective, renewable energy solutions that help them reduce their dependence on traditional energy sources, reducing Co2 emissions. Solar Night Industries, Inc. is based in St. Louis, Missouri (USA). For more information, visit www.SolarNightIndustries.com.

SLND News:

January 2 - Solar Night Industries Offers Unique Program to Jump-Start New Home Sales

Solar Night Industries (OTC: SLND), a renewable energy company formed to accelerate the adoption of Modern Energy Solutions, introduces the Solar Synapse(TM), a product, sales and marketing program designed to capitalize on the burgeoning demand for renewable energy alternatives among potential new homeowners. According to a recent Roper survey commissioned by Sharp Electronics Corporation, nearly 90 percent of Americans think that solar electricity should be an option for all new home construction. Three-quarters of survey respondents perceive solar power to be more important than ever, evidence that Americans recognize the value of solar as a modern, renewable form of energy.

The Solar Synapse Pre-Wire Kit is part of an overall program designed to empower homeowners to add energy efficiency in the future. The Kit, installed during construction, will prepare a new home for adding photovoltaic solar panels (electricity) at some future date. With new federal, state and local subsidies changing and the price of solar panels projected to halve in the next five years, the timing is perfect to make these new homes "solar ready" now. The program includes marketing materials to help the builder sell Pre-Wire Kits and provides a post-purchase activity for the new homeowner. After closing, new owners can go to the Solar Synapse (TM) site to register their kit. They will receive a copy of a "The Homeowner's Guide to Renewable Energy," plus they qualify to receive a Modern Energy Plan(TM) from SNI for their home. The revolutionary Modern Energy Plan(TM) is a customized plan that will tell them the cost to complete the total solar system, plus, educate the consumer regarding the incentives in their area.

"We feel the Solar Synapse(TM) is a unique solution for builders who seek to differentiate their business and attract the mainstreaming green market. Education is an important aspect of our business model and we believe this program teaches builders about the potential of using modern energy solutions as a best-practice, and educating the homeowner regarding their options," says Tim Corbet, CEO of Solar Night.

Solar Night is expanding the Solar Synapse(TM) product rollout via a network of Manufacturer's Representatives' from the building and renewable energy segments. For more information, go to www.SolarSynapse.com.

DOR BIOPHARMA INCORPORATED (OTCBB: DORB)
"Up 13.16% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/DORB.php

DOR BioPharma, Inc., a biopharmaceutical company, engages in the research and development of oral therapeutic products intended for areas of unmet medical needs and biodefense vaccines in the United States and internationally. It operates through two segments, BioTherapeutics and BioDefense. The BioTherapeutics segment develops orBec, an orally administered corticosteroid that exerts a potent and local anti-inflammatory effect in the mucosal tissue of the gastrointestinal tract; Oraprine, an oral suspension of azathioprine; and LPE and PLP systems for delivery of water-insoluble drugs. The BioDefense segment offers RiVax, ricin toxin vaccine, a heat stable toxin that is isolated and purified from the bean of the castor plant; and BT-VACC, the Botulinum toxin, a poisonous natural substance that causes acute, symmetric, and descending flaccid paralysis due to its action on peripheral cholinergic nerves. The company was founded in 1987 and is based in Ewing, New Jersey.

DORB News:

January 3 - DOR BioPharma Receives Orphan Drug Designation for Oral BDP for the Treatment of Pediatric Crohn's Disease

Treatment Could Benefit Approximately 100,000 Pediatric Patients in the US Afflicted With Crohn's Disease

DOR BioPharma, Inc. (OTCBB: DORB) ("DOR" or the "Company") announced that the Office of Orphan Products Development of the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to Oral BDP (beclomethasone dipropionate) for the treatment of pediatric Crohn's disease.

The US Orphan Drug Act is intended to assist and encourage companies to develop safe and effective therapies for the treatment of rare diseases and disorders. In addition to providing a seven year term of market exclusivity for Oral BDP upon final FDA approval, orphan drug designation also positions DOR to be able to take advantage of a wide range of financial and regulatory benefits, including government grants for conducting clinical trials, waiver of expensive FDA user fees for the potential submission of a New Drug Application for Oral BDP, and certain tax credits.

Oral BDP is a highly potent, topically active corticosteroid that has a local effect on inflamed tissue. BDP has been marketed in the United States and worldwide since the early 1970s as the active pharmaceutical ingredient in inhalation products for the treatment of patients with allergic rhinitis and asthma. BDP is also the active ingredient in orBec®, currently in development by DOR for the treatment and prevention of Graft-versus-Host disease (GVHD).

"The FDA's decision to grant Oral BDP Orphan Drug Designation for the treatment of pediatric Crohn's disease signifies an important step for DOR as we begin to expand our pipeline with Oral BDP into other important indications beyond GVHD," stated Christopher J. Schaber, PhD, President and CEO of DOR BioPharma. "We anticipate that pediatric Crohn's disease will be the first of several new Orphan Drug Designations both in the US and in Europe as we work to maximize the global value of our Oral BDP and orBec® franchise. We believe that Oral BDP has the potential to be of significant benefit to pediatric Crohn's disease patients."

ABOUT PEDIATRIC CROHN’S DISEASE

Crohn's disease is an ongoing disorder that causes inflammation of the gastrointestinal (GI) tract. Crohn's disease can affect any area of the GI tract, from the mouth to the anus, but it most commonly affects the lower part of the small intestine, called the ileum. The swelling caused by the disease extends deep into the lining of the affected organ. The swelling can induce pain and can make the intestines empty frequently, resulting in diarrhea. Because the symptoms of Crohn's disease are similar to other intestinal disorders, such as irritable bowel syndrome and ulcerative colitis, it can be difficult to diagnose. People of Jewish heritage have an increased risk of developing Crohn's disease.

Crohn's disease can appear at any age, but it is most often diagnosed in adults in their 20s and 30s. However, approximately 30% of people with Crohn's disease develop symptoms before 20 years of age. Pediatric Crohn's disease is a subpopulation of patients 0-19 years of age who suffer from Crohn's disease. In the United States, about 100,000 teens and preteens have Crohn's disease.

Crohn's disease presents special challenges for children and teens. In addition to bothersome and often painful symptoms, the disease can stunt growth, delay puberty, and weaken bones. Crohn's disease symptoms may sometimes prevent a child from participating in enjoyable activities. The emotional and psychological issues of living with a chronic disease can be especially difficult for young people.

ABOUT ORAL BDP

Beclomethasone dipropionate is a highly potent, topically active corticosteroid and is the active ingredient in orBec®, DOR's product candidate for the treatment of gastrointestinal Graft-versus-Host disease (GI GVHD), a common disorder among immunocompromised cancer patients after receiving allogeneic stem cell or bone marrow transplants. Like pediatric Crohn's disease, GI GVHD is also an inflammatory condition of the GI tract. Patients with mild-to-moderate GI GVHD typically develop symptoms of anorexia, nausea, vomiting and diarrhea.

DOR has previously run two randomized, double-blinded, placebo-controlled clinical trials in GI GVHD with orBec®. The first trial was a 60-patient Phase 2 single-center clinical trial conducted at the Fred Hutchinson Cancer Research Center. The second trial was a 129-patient pivotal Phase 3 multi-center clinical trial conducted at 16 leading bone marrow/stem cell transplant centers in the United States and France. Although orBec® did not achieve statistical significance in the primary endpoint of its pivotal trial, namely median time to treatment failure through Day 50 (p-value 0.1177), orBec® did achieve statistical significance in other key secondary endpoints such as median time to treatment failure through Day 80 (p-value 0.0226), as well as a 66% reduction in mortality among patients randomized to orBec® at 200 days post-transplant with only five patient (8%) deaths in the orBec® group compared to 16 patient (24%) deaths in the placebo group (p-value 0.0139). At one year post randomization in the pivotal Phase 3 trial, 18 patients (29%) in the orBec® group and 28 patients (42%) in the placebo group died within one year of randomization (46% reduction in mortality, hazard ratio 0.54, 95% CI: 0.30, 0.99, p=0.04, stratified log-rank test).

WIRELESS AGE COMMUNICATIONS (OTCBB: WLSA)
"Up 11.86% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/WLSA.php

Wireless Age Communications, through its 99.7% owned subsidiary, Wireless Age Communications Ltd., is in the business of operating retail cellular and telecommunications outlets in cities in western Canada. Through its other wholly owned subsidiary, Wireless Source Distribution Ltd., the company distributes two-way radio products, prepaid phone cards, wireless accessories and various battery and ancillary electronics products in Canada.

WLSA News:

January 3 - Wireless Age Achieves Record Fourth Quarter Revenues

Wireless Age Communications, Inc. (OTCBB: WLSA) ("Wireless Age") announced record unaudited consolidated revenues for the fourth quarter of fiscal 2007.

Unaudited revenues for the fourth quarter of 2007 were approximately CAD$10,844,000, compared to approximately CAD$7,871,000 during the fourth quarter of 2006, representing an increase of approximately 38%. Unaudited fiscal 2007 revenues were approximately CAD$34,666,000 compared to CAD$27,085,000 from continuing operations in 2006, representing year over year growth of 28%.

Retail segment revenues grew by 33% from approximately CAD$4,697,000 in the fourth quarter of 2006 to approximately CAD$6,232,000 in 2007. Annual retail segment revenues were up by 20% at approximately CAD$18,826,000 in 2007 and CAD$15,679,000 in 2006.

Commercial segment revenues grew by 45% from approximately CAD$3,174,000,000 in the fourth quarter of 2006 to approximately CAD$4,612,000 in 2007. Fiscal 2007 commercial segment revenues were up by 39% at approximately CAD$15,840,000 compared to CAD$11,406,000 in 2006.

Allen Cowie, Wireless Age retail segment President commented; "2007 has been a great year and the fourth quarter topped it off. Extremely strong demand was led by very aggressive cellular plan pricing launched in the Manitoba market in early November. This drove year over year post paid handset growth by over 50% and as much as 90% in some of our Manitoba locations in the months of November and December. The timing of the acquisition we made in Selkirk on November 1st could not have been better. As usual, our staff did an outstanding job in meeting the tremendous demands of a great fourth quarter. This continued growth in the wireless market was echoed in our commercial segment in particular in the cellular prepaid cards and accessory product lines."

John G. Simmonds, Wireless Age CEO stated; "This has been a pivotal year for Wireless Age. Business continues to exceed all of our expectations and we look forward to 2008 with great optimism. I want to congratulate our staff on a job well done and thank our shareholders for their loyal support during our turnaround."